Pycnogenol® for Menstrual Discomfort

Most women of child-bearing age experience a variety of symptoms related to the menstrual cycle that may be limited to milder discomfort such as the pre-menstrual syndrome or extend to serious menstrual pain which seriously affects quality of life. The complete replacement of tissue lining the uterine cavity, the endometrium, during the menstrual period represents a wound healing process and involves inflammatory processes.

The inflammation is initiated by prostaglandins developing during menstruation which causes uterine contractions and pain. Some women experience menstrual pain levels which severely interfere with daily functions and affects quality of life. In medical terminology this is known as dysmenorrhoea.

The prevalence of dysmenorrhoea is highest in adolescent women, with estimates ranging from 20% to 90% depending on the diagnosis standards applied [French, 2005]. For women dysmenorrhoea is the most common reason for absence from work.

Pycnogenol® inhibits prostaglandins and is anti-inflammatory

The standard regimen for dysmenorrhoea are “over the counter” non-steroidal antiinflammatory drugs (NSAID) such as ibuprofen. These medications reduce menstrual pain efficiently and quite rapidly. However, these pain-killers have side effects causing gastric problems and other more serious complications, particularly when they are taken in high quantities as it is typical in dysmenorrhoea. A clinical study has shown that consumption of Pycnogenol® non-selectively inhibits cyclo-oxygenase (COX) enzymes, which are involved in synthesis of pro-inflammatory prostaglandins during the menstrual period. Already after a single dose of Pycnogenol® both COX-1 and COX-2 enzymes are significantly inhibited in humans by 22.5% and 14.7%, respectively [Schäfer et al., 2006].

Furthermore, Pycnogenol® was shown to lower the inflammatory “master switch” nuclear factor kappa B (NF-kB) in humans after five days of continuous consumption by 15.8% [Grimm et al., 2006]. NF-kB triggers the generation of essentially all pro-inflammatory mediators. This provides the basis for the rationale to use Pycnogenol® to naturally moderate inflammatory processes and pain sensation involved in menstruation. Additionally, Pycnogenol® supports the wound healing process and stabilises capillaries which will help to speed-up the recovery of the endometrium.

Japanese gynaecologists discovered Pycnogenol® soothes menstrual pain

Two Japanese gynaecologists tested Pycnogenol® for lowering menstrual pain in an open, uncontrolled exploratory trial. Thirty nine women with dysmenorrhoea or endometriosis were treated with 30 mg
Pycnogenol® daily starting seven days before menstruation. Both abdominal pain and cramping were found to be improved in the majority of women [Kohama & Suzuki, 1999]. These initial findings have prompted further research of benefits of Pycnogenol® for menstrual discomfort.

**Pycnogenol® relieves menstrual pain**

A clinical trial in Japan investigated 47 women who were diagnosed having symptoms of dysmenorrhoea. Their pain sensation and use of pain medication was recorded throughout the trial, which covered three complete menstrual cycles. The first, pre-treatment menstrual cycle served for establishing baseline pain level and analgesic use. Directly after completion of the pre-treatment cycle women took Pycnogenol® every day until completion of two further menstrual cycles.

The results showed that women had significantly less abdominal pain when they had started taking Pycnogenol® three weeks before their period. The pain relief was even more pronounced during the following period, with the pain score reduced by 36% compared to pre-treatment. The number of days during which women experienced menstrual pain was likewise lowered from average pre-treatment 3.9 days to 3.6 and 3.3 days in the first and second period, respectively. Women required less pain medication during their menstrual period when they took Pycnogenol®.

Multi-centre field study with Pycnogenol® for menstrual pain

Four hospitals in Japan investigated a total number of 116 women suffering from menstrual pain in a multi-centre, randomised, double-blind, placebo-controlled fashion [Suzuki et al., 2007]. The first two pre-treatment menstrual cycles were utilised for establishing base-line values for pain sensation and analgesic medication use. During the following 2 menstrual cycles women were randomly assigned to groups receiving daily regimens of Pycnogenol® or placebo. Thereafter, regimen was discontinued to investigate the recurrence of symptoms.

Treatment with Pycnogenol® lowered pain during menstruation, which was reflected by a significant reduction of pain medication used. The number of painful days due to dysmenorrhoea was decreased from average 2.1 days prior to treatment to 1.3, and to 1.3 and 1.2 days during the consecutive menstrual cycles, respectively. Discontinuation does not cause an immediate relapse as pain levels and pain medication use did not increase. As in previous studies on dysmenorrhoea the pain relief develops gradually during supplementation with Pycnogenol®.
Endometriosis
Endometriosis is a condition involving the tissue that covers the uterine cavity (endometrium), which is shed during menstruation. In endometriosis this tissue has moved outside the uterus and grown elsewhere in the body. The most common places with displaced endometrium are the ovaries, the oviducts, the uterine wall, lining of the pelvis and even the bladder and intestines. How the endometrial cells reach other organs remains unknown. The displaced tissue behaves like uterine endometrium in responding to the monthly cycle. Bleeding occurs but cells cannot exit the body, and painful inflammation erupts. In every cycle the growths adds extra tissue and for this reason endometriosis symptoms tend to get worse over time.

Standard treatment involves NSAIDs for pain relief. In more advanced cases surgery is considered the best treatment option. Hormonal treatment is commonly applied for treatment of endometriosis. Oral contraceptives block the effects of natural hormones on endometrial growth, which can make endometriosis less painful. The most effective treatment is achieved with the synthetic peptide Leuprorelin which blocks oestrogen production. Leuprorelin cannot be taken orally and therefore a long-lasting depot is injected under the skin. The disadvantage of Leuprorelin is the interruption of menses and women cannot get pregnant. The treatment is limited to 6 months because of the risk for osteoporosis and after discontinuation a relapse is very likely.

Pycnogenol® is helpful for women with endometriosis
The possibility of improving endometriosis with Pycnogenol® was investigated in a comparative clinical study with 58 women receiving either Pycnogenol® or Leuprorelin [Kohama et al., 2007]. All women had undergone surgical treatment of endometriosis within 6 months prior to participation. They suffered recurrent moderate to severe endometriosis and refused further surgery.

Treatment with Pycnogenol® gradually decreased menstrual pain from initial severe pain to moderate pain at trial end. The pain score was lowered significantly by 33% during the treatment period. Leuprorelin suppressed menstruation during treatment. Pycnogenol® was effective for slowly but steadily decreasing pelvic pain from initial severe to moderate pain. Leuprorelin was significantly more effective; however, a dramatic relapse occurred within 24 weeks after obligate discontinuation.

A specific antigen (CA-125) is shed from inflamed endometriomas into the blood stream and serum CA-125 is considered a good marker for evaluation of the severity of advanced endometriosis. Pycnogenol® significantly lowered serum CA-125 indicating a reduction of endometrioma size. Lowering of CA-125 was dramatically more effective with Leuprorelin, however, values almost returned to baseline after discontinuation.

As expected Leuprorelin drastically lowered women’s oestrogen level. In contrast, over the whole treatment period Pycnogenol® did not influence women’s oestrogen level.
In conclusion, Pycnogenol® is significantly effective for improving endometriosis, though it is not as effective as oestrogen-inhibition with Leuprorelin. The advantage of Pycnogenol® is the absence of severe side effects. Interestingly, five women with endometriosis taking Pycnogenol® left the study because they became pregnant.

The application of Pycnogenol® for dysmenorrhoea and endometriosis is patented (US patent 6,372,266).

References


The information provided in this document is for professional use only. Statements and information provided herein have not been evaluated by the Food and Drug Administration or other health authorities. This product is not intended to diagnose, treat, cure or prevent any disease. Horphag Research supplies Pycnogenol® as a raw material to manufacturers of finished products. Therefore, Horphag Research makes no claims regarding the use of finished products and each manufacturer is responsible for ensuring that any claims it chooses to make in connection with the use of its finished products fully comply with the regulatory and legal requirements of the locations in which it markets its products.